Poseida Therapeutics Inc (PSTX)

[subslover]

Poseida Therapeutics Inks Collaboration With Roche
August 03 2022 - 08:18AM
Dow Jones News
Alert
Print
Share On Facebook
By Colin Kellaher


Poseida Therapeutics Inc. on Wednesday said it signed a collaboration and license agreement potentially worth billions of dollars with Swiss pharmaceutical company Roche Holding AG.

San Diego-based Poseida, a clinical-stage biopharmaceutical company, said the deal covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications.

Poseida said it would receive an upfront payment of $110 million, and that it could receive up to $110 million in near-term milestones and other payments over the next several years.

It also said it is eligible to receive up to $6 billion in research, development, launch and other payments, along with royalties on product sales.

Trading in shares of Poseida, which closed Tuesday at $2.43, was halted premarket on Wednesday.